Ionis Pharmaceuticals announced that it will present new three-year data from the Phase 2 open-label extension study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company’s investigational RNA-targeted prophylactic medicine for hereditary angioedema. Results will be presented at the 2024 American College of Allergy, Asthma & Immunology, ACAAI, Annual Scientific Meeting in Boston, Massachusetts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis announces U.S. FDA granted Fast Track Designation for zilganersen
- Biotech Alert: Searches spiking for these stocks today
- Oracle reports Q1 beat, EU says Apple must pay: Morning Buzz
- Ionis Pharmaceuticals 11.5M share Spot Secondary priced at $43.50
- Ionis Pharmaceuticals announces $500M common stock offering